Advertisement
Screener

AMNEAL PHARMACEUTICALS, INC. (AMRX) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets

AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $24.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06

  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $10.75M, a 13.13% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $13.40M, a 2512.09% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.01M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $10.16M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $19.16M, a 1898.23% increase from fiscal 2024.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $959.00K.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$37.81M.
  • AMNEAL PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$9.88M, a 144.96% decline from fiscal 2021.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 month as first filedIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month as first filed
2026-06-30$10.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$24.15M
10-Q · filed 2026-08-06
$23.14M
derived: sum of 3 quarters · filed 2026-08-06
$33.30M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$13.40M
10-Q · filed 2026-05-07
$12.39M
derived: sum of 2 quarters · filed 2026-05-07
$22.55M
derived: sum of 3 quarters · filed 2026-05-07
$32.05M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$1.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$9.15M
derived: sum of 2 quarters · filed 2026-02-27
$18.65M
derived: sum of 3 quarters · filed 2026-08-06
$19.16M
10-K · filed 2026-02-27
2025-09-30$10.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$19.66M
derived: sum of 2 quarters · filed 2026-08-06
$20.17M
10-Q · filed 2025-11-06
$19.05M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$9.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$10.02M
10-Q · filed 2026-08-06
$8.89M
derived: sum of 3 quarters · filed 2026-08-06
$2.56M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$513.00K
10-Q · filed 2026-05-07
-$610.00K
derived: sum of 2 quarters · filed 2026-05-07
-$6.95M
derived: sum of 3 quarters · filed 2026-05-07
-$10.24M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$7.46M
derived: sum of 2 quarters · filed 2026-02-27
-$10.75M
derived: sum of 3 quarters · filed 2026-02-27
$959.00K
10-K · filed 2026-02-27
2024-09-30-$6.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$9.63M
derived: sum of 2 quarters · filed 2025-11-06
$2.08M
10-Q · filed 2025-11-06
-$10.92M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30-$3.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$8.42M
10-Q · filed 2025-08-07
-$4.59M
derived: sum of 3 quarters · filed 2026-02-27
$2.50M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$11.71M
10-Q · filed 2025-05-07
-$1.30M
derived: sum of 2 quarters · filed 2026-02-27
$5.79M
derived: sum of 3 quarters · filed 2026-02-27
$3.05M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31-$13.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
-$5.92M
derived: sum of 2 quarters · filed 2026-02-27
-$8.65M
derived: sum of 3 quarters · filed 2026-02-27
-$37.81M
10-K · filed 2026-02-27
2023-09-30$7.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$4.35M
derived: sum of 2 quarters · filed 2024-11-12
-$24.81M
10-Q · filed 2024-11-12
-$69.07M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30-$2.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$31.90M
10-Q · filed 2024-08-09
-$76.16M
derived: sum of 3 quarters · filed 2025-02-28
-$161.53M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31-$29.16M
10-Q · filed 2024-05-08
-$73.42M
derived: sum of 2 quarters · filed 2025-02-28
-$158.79M
derived: sum of 3 quarters · filed 2025-02-28
-$43.47M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31-$44.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
-$129.63M
derived: sum of 2 quarters · filed 2025-02-28
-$14.30M
derived: sum of 3 quarters · filed 2025-02-28
-$9.88M
10-K · filed 2025-02-28
2022-09-30-$85.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$29.96M
derived: sum of 2 quarters · filed 2023-11-09
$34.38M
10-Q · filed 2023-11-09
$28.87M
derived: sum of 4 quarters · filed 2024-03-14
2022-06-30$115.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$119.75M
10-Q · filed 2023-08-08
$114.23M
derived: sum of 3 quarters · filed 2024-03-14
$117.74M
derived: sum of 4 quarters · filed 2024-03-14
2022-03-31$4.42M
10-Q · filed 2023-05-09
-$1.09M
derived: sum of 2 quarters · filed 2024-03-14
$2.42M
derived: sum of 3 quarters · filed 2024-03-14
$27.01M
derived: sum of 4 quarters · filed 2024-03-14
2021-12-31-$5.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$2.01M
derived: sum of 2 quarters · filed 2024-03-14
$22.58M
derived: sum of 3 quarters · filed 2024-03-14
$21.98M
10-K · filed 2024-03-14
2021-09-30$3.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$28.09M
derived: sum of 2 quarters · filed 2022-11-07
$27.49M
10-Q · filed 2022-11-07
$11.82M
derived: sum of 4 quarters · filed 2023-03-03
2021-06-30$24.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$23.99M
10-Q · filed 2022-08-08
$8.31M
derived: sum of 3 quarters · filed 2023-03-03
-$552.00K
derived: sum of 4 quarters · filed 2023-03-03
2021-03-31-$602.00K
10-Q · filed 2022-05-06
-$16.28M
derived: sum of 2 quarters · filed 2023-03-03
-$25.14M
derived: sum of 3 quarters · filed 2023-03-03
-$60.30M
derived: sum of 4 quarters · filed 2023-03-03
2020-12-31-$15.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
-$24.54M
derived: sum of 2 quarters · filed 2023-03-03
-$59.70M
derived: sum of 3 quarters · filed 2023-03-03
-$33.31M
10-K · filed 2023-03-03
2020-09-30-$8.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$44.02M
derived: sum of 2 quarters · filed 2021-11-08
-$17.64M
10-Q · filed 2021-11-08
-$15.25M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$35.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$8.77M
10-Q · filed 2021-08-09
-$6.39M
derived: sum of 3 quarters · filed 2022-03-01
-$19.03M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$26.38M
10-Q · filed 2021-05-07
$28.77M
derived: sum of 2 quarters · filed 2022-03-01
$16.13M
derived: sum of 3 quarters · filed 2022-03-01
$10.17M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$2.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$10.26M
derived: sum of 2 quarters · filed 2022-03-01
-$16.21M
derived: sum of 3 quarters · filed 2022-03-01
-$38.87M
10-K · filed 2022-03-01
2019-09-30-$12.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$18.60M
derived: sum of 2 quarters · filed 2020-11-06
-$41.26M
10-Q · filed 2020-11-06
-$40.23M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$5.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$28.61M
10-Q · filed 2020-08-06
-$27.59M
derived: sum of 3 quarters · filed 2021-03-01
-$42.50M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$22.66M
10-Q · filed 2020-05-11
-$21.63M
derived: sum of 2 quarters · filed 2021-03-01
-$36.54M
derived: sum of 3 quarters · filed 2021-03-01
-$29.94M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$1.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$13.88M
derived: sum of 2 quarters · filed 2021-03-01
-$7.28M
derived: sum of 3 quarters · filed 2021-03-01
-$8.78M
10-K · filed 2021-03-01
-$19.20M
10-K · filed 2019-03-01
2018-09-30-$14.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$8.31M
derived: sum of 2 quarters · filed 2019-11-07
-$9.80M
10-Q · filed 2019-11-07
-$3.10M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$6.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05
$5.11M
10-Q · filed 2019-08-05
-$711.00K
10-Q · filed 2018-08-09
$11.81M
derived: sum of 3 quarters · filed 2020-03-02
$24.46M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$1.49M
10-Q · filed 2019-05-09
$5.21M
derived: sum of 2 quarters · filed 2020-03-02
$17.86M
derived: sum of 3 quarters · filed 2020-03-02
2017-12-31$6.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$19.35M
derived: sum of 2 quarters · filed 2020-03-02
$25.30M
10-K · filed 2020-03-02
2017-09-30$12.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$18.60M
10-Q · filed 2018-11-07
2017-06-30$5.96M
10-Q · filed 2018-08-09
2016-12-31-$2.04M
10-K · filed 2019-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liquidia Corp (LQDA)United States$6.347B51.23
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Alkermes plc. (ALKS)$6.844B132.74
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07